Quality Agreement in Pharma: Essential Elements and Regulatory Requirements

Quality Agreement in Pharma: Essential Elements and Regulatory Requirements

A quality agreement is the foundational document governing quality responsibilities between parties involved in pharmaceutical manufacturing, testing, packaging, or distribution. It defines who does what, who approves what, and who bears responsibility when something goes wrong. Without a well-constructed quality agreement, contract manufacturing arrangements introduce uncontrolled risk into the pharmaceutical supply chain.

The regulatory expectation is unambiguous. EU GMP Annex 16 and Chapter 7 mandate written contracts. FDA's 2016 guidance on contract manufacturing arrangements explicitly states that quality agreements are essential. Yet quality agreements remain one of the most frequently cited deficiency areas during regulatory inspections, often because they are incomplete, outdated, or fail to address critical quality scenarios.

This guide covers the regulatory basis, required elements, common deficiencies, and practical structuring of pharmaceutical quality agreements.

In this guide, you'll learn:

• The regulatory framework governing quality agreements across FDA and EMA jurisdictions
• Every essential element that must be included
• How to allocate responsibilities for change control, deviations, complaints, and recalls
• Common deficiencies cited in Warning Letters and inspection observations
• Template structure for building compliant quality agreements

Regulatory Framework for Quality Agreements

EU GMP Requirements

EU GMP provides the most explicit regulatory framework for quality agreements.

Chapter 7 (Outsourced Activities) requires:

• A written contract between contract giver and contract acceptor
• Clear definition of responsibilities for each party
• The contract giver retaining ultimate responsibility for product quality
• The contract must allow the contract giver to audit the contract acceptor

Key EU GMP Chapter 7 provisions:

Annex 16 (Certification by a Qualified Person and Batch Release) further requires that the Qualified Person (QP) has access to all information necessary for batch certification, which must be ensured through the quality agreement.

FDA Requirements and Guidance

FDA's regulatory framework for quality agreements is less prescriptive than EMA's but no less important.

21 CFR 211 (Current Good Manufacturing Practice):

• Section 211.22: Quality control unit responsibilities cannot be abdicated through outsourcing
• Section 211.84: Testing and approval of components, containers, and closures applies regardless of who performs the work
• Section 211.142: Warehousing procedures apply to contracted warehousing
• Section 211.160: Laboratory controls requirements extend to contract laboratories

FDA Guidance for Industry: Contract Manufacturing Arrangements for Drugs: Quality Agreements (2016):

This guidance document, though non-binding, represents FDA's current expectations. Key positions include:

• Quality agreements should be distinct from commercial supply agreements
• The quality agreement should address all GMP activities performed by the contract facility
• The agreement should be reviewed and updated regularly
• FDA expects the owner of the NDA/ANDA/BLA to retain ultimate quality responsibility

FDA Warning Letter trends: FDA has cited inadequate quality agreements in numerous Warning Letters issued to contract manufacturers, frequently noting failure to define deviation reporting timelines, lack of change control notification requirements, and absence of audit provisions.

ICH Q10 Alignment

ICH Q10 (Pharmaceutical Quality System) Section 2.7 addresses outsourced activities and management of contract manufacturers. It emphasizes that the pharmaceutical quality system of the contract giver must extend to control and review of outsourced activities.

Essential Elements of a Quality Agreement

A comprehensive pharmaceutical quality agreement must address the following areas.

1. Scope and Definitions

2. Quality Management Responsibilities

Responsibility matrix structure:

3. Change Control

Change control is the single most contentious area in quality agreements. The agreement must specify:

• Notification requirements: Which changes require prior approval vs. notification only
• Timelines: How far in advance notification must be provided (typically 60-180 days for significant changes)
• Classification of changes: Which changes are considered major, moderate, or minor
• Regulatory assessment: Who determines whether a change requires a regulatory filing (e.g., Prior Approval Supplement, Changes Being Effected supplement per 21 CFR 314.70)
• Emergency changes: Procedures for changes required for safety reasons

Categories of changes requiring notification:

4. Deviation and Investigation Handling

The agreement must define:

• Deviation classification criteria used by the contract acceptor
• Notification timelines (e.g., critical deviations within 24 hours, major within 72 hours, minor in the monthly quality report)
• Investigation responsibilities: Who investigates, who reviews, who approves
• Impact assessment: Who determines whether a deviation affects product quality or previously released batches
• CAPA approval: Whether the contract giver must approve corrective and preventive actions
• Documentation access: Contract giver's right to review deviation investigation records

5. Complaint and Adverse Event Handling

6. Recall and Market Action

• Notification requirement: Immediate notification of any condition that may warrant a recall
• Decision authority: Contract giver holds final recall decision authority
• Traceability: Contract acceptor must maintain complete traceability for all lots manufactured
• Retained samples: Availability and quantity of retained samples for investigation
• Mock recall capability: Contract acceptor must demonstrate ability to trace all materials within defined timelines (typically 24 hours)
• Cost allocation: Who bears the cost of recall activities (typically addressed in the commercial agreement)

7. Audit and Inspection Rights

Per both EU GMP Chapter 7 and FDA expectations:

• Contract giver audit rights: Unrestricted right to audit the contract acceptor's facilities, records, and operations
• Audit frequency: Typically annually, with provisions for "for cause" audits at any time
• Regulatory inspection notification: Contract acceptor must notify the contract giver within 24 hours of any regulatory inspection relevant to the contracted products
• Inspection observation sharing: Contract acceptor must share all inspection observations, 483s, Warning Letters, or equivalent documents
• Response review: Contract giver's right to review and approve regulatory responses
• Third-party audits: Provisions for third-party audits and acceptability

8. Release and Disposition

• Batch release authority: Clearly defined (in the EU, the QP of the marketing authorization holder has ultimate release responsibility per Annex 16)
• Release criteria: Specifications, in-process controls, and acceptance criteria
• Certificate of Analysis: Format, content, and delivery timeline
• Certificate of Compliance: GMP compliance certification per batch
• Rejected batch handling: Disposition, investigation requirements, and notification

9. Documentation and Record Retention

• Batch record retention: Duration (per 21 CFR 211.180, at least 1 year after batch expiry date, or at least 3 years after distribution of the batch)
• Access to records: Contract giver's right to obtain copies of all GMP-relevant documents
• Data integrity: Requirements for compliance with 21 CFR Part 11 and EU Annex 11 (as applicable to electronic records)
• Archival conditions: Requirements for secure, climate-controlled storage

Common Quality Agreement Deficiencies

Findings from FDA Warning Letters and EMA Inspections

Root Causes of Deficient Quality Agreements

1. Written by legal, not quality. Quality agreements drafted by legal teams without quality input often address commercial terms but miss technical GMP requirements.
2. Copied from templates without customization. Generic templates fail to address product-specific or process-specific quality scenarios.
3. Not updated after changes. Quality agreements written at the start of a relationship and never revised become obsolete.
4. Conflicting documents. Quality agreement contradicts the commercial supply agreement or the Technical Agreement.
5. Unilateral drafting. One party drafts the agreement without meaningful input from the other, resulting in impractical or unclear obligations.

Quality Agreement vs. Supply Agreement vs. Technical Agreement

FDA's 2016 guidance explicitly recommends separating the quality agreement from the commercial supply agreement to avoid situations where quality provisions are subordinated to commercial negotiations. In practice, some organizations integrate these documents, but distinct agreements are the preferred approach.

Quality Agreement Template Structure

A well-organized quality agreement typically follows this structure:

Section 1: General Provisions

• Purpose and scope
• Definitions
• Applicable regulations and guidelines
• Effective date and review cycle

Section 2: Roles and Responsibilities

• Contract giver responsibilities
• Contract acceptor responsibilities
• Responsibility matrix (detailed table)

Section 3: Quality System Requirements

• Change control
• Deviation management
• CAPA management
• Document control
• Training

Section 4: Manufacturing and Testing

• Raw materials and components
• Manufacturing process controls
• In-process testing
• Release testing
• Stability testing

Section 5: Compliance and Regulatory

• Regulatory filings and notifications
• Inspection management
• Audit program
• Annual Product Review / Product Quality Review

Section 6: Product Protection

• Complaint handling
• Recall management
• Returned goods
• Counterfeit prevention

Section 7: Documentation and Data

• Batch documentation
• Record retention
• Data integrity
• Certificates (COA, COC)

Section 8: Agreement Management

• Review and amendment process
• Dispute resolution
• Termination provisions
• Transition planning

Appendices:

• Product list and specifications
• Key contact information
• Approved supplier lists
• Communication templates

Best Practices for Quality Agreement Management

Negotiation and Development

1. Start early. Begin quality agreement discussions at the vendor qualification stage, not after manufacturing has started.
2. Involve quality from the start. Quality professionals must be involved in drafting, not just reviewing the final document.
3. Use a responsibility matrix. A RACI (Responsible, Accountable, Consulted, Informed) matrix eliminates ambiguity.
4. Define escalation paths. Establish clear escalation procedures for quality disputes.
5. Align with regulatory filings. Ensure the quality agreement reflects commitments made in marketing authorization applications and DMFs.

Maintenance and Review

• Periodic review: Review quality agreements at least annually, or whenever a significant change occurs (per FDA 2016 guidance recommendation)
• Trigger-based review: Any major change in process, personnel, regulations, or regulatory status should trigger a review
• Version control: Maintain clear version history with dates and signatures
• Metrics tracking: Track agreement compliance through quality indicators (e.g., on-time deviation notifications, change control compliance)

Multi-Site and Multi-Product Considerations

For contract givers working with multiple contract acceptors, or contract acceptors serving multiple contract givers:

• Master quality agreement: Consider a master agreement with product-specific appendices
• Harmonized expectations: Align quality expectations across contract acceptors to ensure consistent product quality
• Tiered approach: Apply more rigorous requirements to higher-risk activities (sterile manufacturing, API synthesis) than lower-risk activities (secondary packaging, warehousing)

Regulatory References

Key Takeaways

References